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Genome Wide Association Studies: Identifying
the Genes that Determine the Risk of
Abdominal Aortic AneurysmAbdominal aortic aneurysm (AAA) is a multifactorial disease
with a strong genetic component. Aside from the major
environmental risk factor of tobacco use, and the un-
modifiable risk factors of advancing age and male gender,
there is compelling evidence for the genetic contribution to
the pathogenesis of AAA, with up to ten-fold increased risk
in first degree relatives of those with AAA.1 However, it is
widely accepted that AAA is unlikely to be associated
with a single gene, and that multiple genetic factors are
responsible.2 This makes identifying the genes involved in
AAA challenging, as conventional approaches that have
been successful for monogenic diseases such as cystic fibro-
sis and Huntingtons disease are not appropriate.
One approach has been through hypothesis-driven asso-
ciation studies, whereby the frequency of a common
variant in a candidate gene is compared between a group
of unrelated affected individuals and unaffected age-
matched controls. The major limitation of this approach
is that the selection of appropriate candidate genes relies
on knowledge of the pathological processes underlying the
disease in question, and since this is currently unclear for
AAA, the choice of genes studied to date has been made on
a ‘best guess’ basis. These studies have recently been
reviewed3 and the genes that have been studied include in-
flammatory mediators, tissue proteases and their inhibi-
tors, those involved in endothelial and smooth muscle cell
biology and those coding for components of the renin-
angiotensin system. While such approaches have often
given inconsistent results in different laboratories, meta-
analysis of the available data has shown some evidence
for modest risk effects associated with common variants
in the genes for Angiotensin Converting Enzyme (Odds Ratio
(OR) 1.33, Methylenetetrahydrofolate reductase (OR
1.14)), and matrix metalloprotease-9 (OR 1.09).
A complementary approach has recently become available
due to advances in genomic investigation and bioinformatics
that have allowed significant proportions of the common
variation in the human genome to be identified and recorded.
These variations consist mainly of single nucleotide1078-5884 ª 2008 European Society for Vascular Surgery. Published by
doi:10.1016/j.ejvs.2008.06.003polymorphisms (SNPs) (DNA nucleotide substitutions) and to
date more than 6 million have been identified and verified.4
Recent technological advances have enabled us to
examine this variation in an affordable way. Array-based
platforms now exist that allow over a million SNPs to be
assayed in a single experiment. This allows us to carry out
Genome-Wide Association Studies (GWAS), and to compare
the variation seen in those with a particular disease to
groups of healthy controls and thus to identify the genes
associated with the disease in a hypothesis-free approach.
However GWAS have particular design and analysis
issues,5 principally sample size requirements. Using con-
ventional statistical analyses with alphaZ 0.05 if 500 000
SNPs were assayed in the same experiment 100 000 signifi-
cant results would be expected, so clearly adjustment for
multiple hypothesis testing must be made. Different
methods exist to allow for this, including the well-known
Bonferroni correction which in this example requires us to
generate a P-value of less than 1 107 to classify a result
as significant. Because of this, sample sizes of at least 2000
cases and 2000 controls are required. Any SNPs showing
a statistically significant effect will then need to be geno-
typed in a second (replication) cohort of similar size to
the initial study cohort and so overall large numbers of
both cases and controls are required.
The utility of GWAS as a tool for genetic investigation of
complex disease has recently been demonstrated by the
Wellcome Trust Case-Control Consortium6 with many new loci
being identified for heart disease, type 2 diabetes etc. (as well
as confirming the contribution of several ‘‘candidate’’ genes).
ForAAAthisapproachhasalreadybornefruit,withaSNPonchro-
mosome 9p21 that was originally identified as being associated
with heart disease recently reported to also be associated with
AAA (ORZ 1.3).7 The nearest genes to this SNP are a cluster
consisting of CDKN2A-ARF-CDKN2B, which code for proteins
that play a role in cell-proliferation, senescence and apoptosis,
all features implicated in atherogenesis. The potential mecha-
nism, by which variants in this chromosome 9 region increase
risk of CHD or AAA, remains to be elucidated.Elsevier Ltd. Open access under CC BY license.
396 EditorialTo exploit the new molecular technologies, an interna-
tional group of investigators from Australia, New Zealand
and the UK have formed ‘‘The Aneurysm Consortium’’ and
recently obtained funding to carry out a GWAS of AAA.
Hopefully this will provide insights into the pathogenesis of
the disease and may identify novel potential targets for
pharmacotherapeutic intervention for small AAA.
The GWA approach also has the potential to drive
forward knowledge of the aetiologies of venous disease
and other forms of peripheral atherosclerosis.
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